CLLS

Cellectis (CLLS)

Cellectis SA

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CLLS

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next >>

Date	Time	Source	Headline	Symbol	Company
01/04/2023	5:04PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
01/04/2023	4:22PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
12/29/2022	4:30PM	GlobeNewswire Inc.	Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases	NASDAQ:CLLS	Cellectis SA
12/28/2022	4:38PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
12/28/2022	4:30PM	GlobeNewswire Inc.	Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities	NASDAQ:CLLS	Cellectis SA
12/22/2022	4:33PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
12/22/2022	4:30PM	GlobeNewswire Inc.	Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL	NASDAQ:CLLS	Cellectis SA
12/13/2022	8:20AM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
12/13/2022	7:30AM	GlobeNewswire Inc.	Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML	NASDAQ:CLLS	Cellectis SA
12/01/2022	10:05PM	TipRanks	Robert W. Baird Keeps Their Buy Rating on Cellectis SA (CLLS)	NASDAQ:CLLS	Cellectis SA
12/01/2022	5:08PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
12/01/2022	4:40PM	GlobeNewswire Inc.	Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022	NASDAQ:CLLS	Cellectis SA
11/10/2022	9:26AM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
11/10/2022	9:05AM	GlobeNewswire Inc.	Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022	NASDAQ:CLLS	Cellectis SA
11/10/2022	8:50AM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
11/10/2022	2:48AM	GlobeNewswire Inc.	Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)	NASDAQ:CLLS	Cellectis SA
11/03/2022	5:10PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
11/03/2022	4:44PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
11/03/2022	4:36PM	GlobeNewswire Inc.	Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022	NASDAQ:CLLS	Cellectis SA
11/03/2022	4:16PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
11/03/2022	4:05PM	GlobeNewswire Inc.	Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022	NASDAQ:CLLS	Cellectis SA
10/27/2022	4:37PM	GlobeNewswire Inc.	Cellectis to Report Third Quarter 2022 Financial Results	NASDAQ:CLLS	Cellectis SA
10/12/2022	12:25AM	TipRanks	Cellectis SA (CLLS) Gets a Buy from Robert W. Baird	NASDAQ:CLLS	Cellectis SA
10/11/2022	4:30PM	GlobeNewswire Inc.	Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022	NASDAQ:CLLS	Cellectis SA
10/06/2022	4:17PM	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:CLLS	Cellectis SA
10/05/2022	4:30PM	GlobeNewswire Inc.	Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting	NASDAQ:CLLS	Cellectis SA
09/28/2022	4:33PM	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CLLS	Cellectis SA
09/28/2022	4:23PM	GlobeNewswire Inc.	Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer	NASDAQ:CLLS	Cellectis SA
09/23/2022	3:45PM	TipRanks	JMP Securities Sticks to Its Buy Rating for Cellectis SA (CLLS)	NASDAQ:CLLS	Cellectis SA
09/01/2022	4:44PM	GlobeNewswire Inc.	Cellectis Announces Participation in Four Upcoming Investor Conferences in September	NASDAQ:CLLS	Cellectis SA